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Background: This study evaluated the absorption, distribution, and excretion of Gallium-68 (68Ga) radionuclide after
a single intravenous (i.v.) injection of 68Ge/68Ga generator eluate in healthy rats. Additionally, human radiation doses
were estimated from the rat data.
Methods: Twenty-one female and 21 male Sprague-Dawley rats were i.v. injected with 47 ± 4 MBq of 68Ge/68Ga
generator eluate, and the radioactivity of excised organs was measured using a gamma counter at 5, 30, 60, 120, or
180 min afterwards (n = 3–7 for each time point). The radioactivity concentration and plasma pharmacokinetic
parameters were calculated. Subsequently, the estimates for human radiation dosimetry were determined.
Additionally, 4 female and 5 male rats were positron emission tomography (PET) imaged for in vivo visualization of
biodistribution.
Results: 68Ga radioactivity was cleared relatively slowly from blood circulation and excreted into the urine, with
some retention in the liver and spleen. Notably, the 68Ga radioactivity in female genital organs, i.e., the uterus and
ovaries, was considerable higher compared with male genitals. Extrapolating from the female and male rat 68Ga
data, the estimated effective dose was 0.0308 mSv/MBq for a 57-kg woman and 0.0191 mSv/MBq for a 70-kg man.
Conclusions: The estimated human radiation burden of the 68Ge/68Ga generator eluate was slightly higher for
females and similar for males as compared with somatostatin receptor ligands 68Ga-DOTANOC, 68Ga-DOTATOC, and
68Ga-DOTATATE, which is probably due to the retention in the liver and spleen. Our results revealed some
differences between female and male rat data, which, at least in part, may be explained by the small sample size.
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Gallium-68 (68Ga)-labeled tracers are increasingly
used in positron emission tomography (PET) for diag-
nostic purposes. The prototypes of 68Ga-labeled PET
imaging agents are the somatostatin receptor ligands,
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provided the original work is properly creditedtoday routinely used for PET imaging of neuroendo-
crine tumors [1–3]. Currently, many other 68Ga-labeled
peptide families are under clinical evaluation, such as bom-
besins (gastrin-releasing peptide receptor ligands), exendins
(glucagon-like peptide 1 receptor ligands), and arginine-
glycine-aspartic acids (RGDs) (integrin receptor ligands). In
addition to oncology, 68Ga-tracer-based PET has been stud-
ied for imaging of inflammation [4].
68Ga offers a cyclotron-independent, convenient, and
low-cost access to PET imaging agents. It is readily
available by elution from a 68Germanium/68Gallium
(68Ge/68Ga) generator possessing a 1-year life spanle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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more, 68Ga has several convenient characteristics, such
as β+ decay 89 %, Eβ+max 1.9 MeV, and a sufficiently
long half-life (67.71 min) for PET imaging.
The purpose of this study was to obtain preclinical in-
formation to support the use of the 68Ge/68Ga generator
eluate for medical application. The absorption, distribu-
tion, and excretion of radioactivity after a single intra-
venous injection of the 68Ge/68Ga generator eluate were
assessed in order to determine the radiation dosimetry
of 68Ga. This study investigated the possible conse-
quences of poor radiolabeling efficiency or in vivo dis-
sociation of the radiolabeled conjugate, i.e., issues
related to the effects produced in the patient by the free
radionuclide. When 68Ga is eluted from 68Ge/68Ga gen-
erator with 0.1 mol/l hydrochloric acid solution, it is in
the form of 68GaCl3. In aqueous solution;
68Ga is in the
form of the hydrated gallium ion [Ga(H2O)6]
3+. Insol-
uble neutral hydroxide colloids 68Ga(OH)3, may precipi-
tated depending on pH (>4) and the concentration of 68Ga.
After intravenous injection, the 68Ga radioactivity can mi-
grate in the blood circulation as free 68Ga3+ or 68Ga3+
bound to transferrin, ferritin, or lactoferrin. Here, the ab-
sorption, distribution, and excretion of 68Ga radioactivity
after a single intravenous (i.v.) injection were studied in
healthy, mature Sprague-Dawley rats up to 3 h, and the es-
timates for human radiation dosimetry were calculated.Methods
All animal experiments were approved by the National Ani-
mal Experiment Board in Finland (ELLA) and the Regional
State Administrative Agency for Southern Finland (ESAVI)
and conducted in accordance with the relevant European
Union Directive. This preclinical study was performed
without randomization and blinding. The healthy, mature
Sprague-Dawley rats were purchased from Harlan, The
Netherlands, and they were of specific pathogen free (SPF)
quality. The rats were left to acclimate for a minimum of
5 days after their arrival before the study. They were housed
at room temperature (18–24 °C) and relative humidity of
40–70 %. Artificial lighting was used, with 12 h of light
(6 a.m. to 6 p.m.) and 12 h of dark (6 p.m. to 6 a.m.). The
animals received regular feed, and tap water was offered ad
libitum. They fasted for 4–6 h prior to the administration
of the 68Ge/68Ga generator eluate.68Ge/68Ga generator eluate
The 68Ge/68Ga generator (Eckert-Ziegler Source No. 1484-
7 with 1850 MBq nominal radioactivity at reference date)
was eluted with 6 ml of 0.1 mol/l hydrochloric acid; the 0.7
−1.2 ml radioactive elution peak was collected and diluted
with phosphate-buffered saline (PBS) (600−860 μl, pH 7 ±
0) for i.v. injection.Biodistribution
Twenty-one female (weight 248 ± 13 g) and 21 male rats
(weight 342 ± 47 g) were examined at five different time
points post-injection (5, 30, 60, 120, and 180 min), with
3–7 female and 3–7 male rats per time point. The animals
were placed in an immobilizer (AgnTho’s AB, Lidingö,
Sweden), and a catheter was inserted in their tail vein. The
rats were i.v. injected with 47 ± 4 MBq of 68Ge/68Ga gen-
erator eluate as a bolus and promptly flushed with physio-
logical saline after injection. Animals were killed with an
overdose of pentobarbital (Mebunat, Orion Pharma,
Finland). Various organs were excised, weighed, and mea-
sured for total radioactivity by using a gamma counter
(1480 Wizard 3" PerkinElmer/Wallac, Turku, Finland)
cross-calibrated with the dose calibrator (VDC-404; Veen-
stra Instruments, Joure, The Netherlands). Of blood, bone,
bone marrow, brown adipose tissue, fat, plasma, skeletal
muscle, skin, and urine, only small samples were taken
and measured for radioactivity and weight. All other
tissues and organs were measured in their entirety. The
residual carcass was assessed with a dose calibrator.
Urine was obtained directly from the urinary bladder
using a needle and syringe, and total radioactivity was
measured as described above. Blood was obtained by
means of cardiac puncture. Radioactivity of whole blood
was measured. Plasma was separated by centrifugation
(2118×g for 5 min at 4 °C), and plasma radioactivity was
measured. The radioactivity concentration was decay
corrected to the time of injection, and the results were
expressed as standardized uptake values (SUV) and per-
centage of injected radioactivity dose per gram of tissue
(%ID/g).
In addition to ex vivo studies, nine animals (five males
309–355 g, four females 245–287 g) were PET imaged for
180 min to visualize whole-body distribution in vivo and to
obtain time-activity curves. The animals were anesthetized
with isoflurane (induction 3 % and maintenance 1.7 %), and
a catheter was inserted in their tail vein. The rats were i.v.
injected with 45 ± 3 MBq of 68Ge/68Ga generator eluate
and imaged by using a High Resolution Research Tomo-
graph (HRRT; Siemens Medical Systems, Knoxville, TN,
USA) PET camera. Both rats were imaged at the same time.
They were kept on a warm pallet during the imaging pro-
cedure. For attenuation correction, a 6-min transmission
scan was obtained using a collimated transmission point
source. The PET imaging data were reconstructed using
the ordered-subsets expectation maximization 3D algo-
rithm (OSEM3D) with attenuation correction based on
transmission source measurement.
Plasma pharmacokinetics
Plasma pharmacokinetic parameters, i.e., the area under
the curve (AUC), elimination rate constant (kel), total
clearance (ClT), and half-life (t1/2), were calculated using
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60, 120, and 180 min after tracer injection. Only one
sample could be obtained from each animal, wherefore
the sampled concentrations from all animals (males and
females separately) were combined in order to produce
the curve of radioactivity concentration vs. time after in-
jection. Since the injected radioactive dose per weight
was not exactly the same in all animals, the plasma SUVs
(radioactivity concentrations corrected by injected dose
and animal weight) were used for calculation. Initial
concentration (C0) was estimated by back-extrapolating
from the log-linear regression of the two first concentra-
tion values (5- and 30-min samples). AUC between 0
and 180 min was calculated using the linear trapezoidal
rule, starting from C0. Log-linear regression of the last
three concentrations (60-, 120-, and 180-min samples)
was used to estimate the AUC from 180 min to infinityTable 1 Organ weights and ex vivo biodistribution of 68Ga/68Ge gen
Tissue/organ Weight (g) 5 min
Adrenal glands 0.067 ± 0.016 0.673 ± 0.111
Blood a 2.909 ± 0.272
Bone (femur, both) a 0.298 ± 0.071
Bone marrow (femur, both) a 0.586 ± 0.133
Brain 1.612 ± 0.103 0.075 ± 0.006
Brown adipose tissue a 0.405 ± 0.017
Colon (without contents) 1.069 ± 0.288 0.289 ± 0.095
Fat (intraperitoneal) a 0.058 ± 0.028
Heart 0.801 ± 0.049 0.723 ± 0.115
Ileum (without contents) 3.322 ± 1.420 0.271 ± 0.040
Kidneys 1.389 ± 0.162 0.773 ± 0.173
Liver 7.179 ± 0.836 1.225 ± 0.374
Lungs 1.117 ± 0.079 0.949 ± 0.212
Ovaries 0.135 ± 0.024 0.574 ± 0.174
Pancreas 1.180 ± 0.225 0.464 ± 0.283
Plasma a 5.083 ± 0.486
Salivary glands 0.496 ± 0.047 0.397 ± 0.099
Skeletal muscle a 0.132 ± 0.048
Skin a 0.096 ± 0.029
Spleen 0.687 ± 0.136 0.493 ± 0.137
Stomach (without contents) 1.184 ± 0.216 0.261 ± 0.060
Thymus 0.305 ± 0.082 0.234 ± 0.003
Thyroids 0.017 ± 0.005 0.516 ± 0.020
Urinary bladder (without contents) 0.068 ± 0.021 0.256 ± 0.080
Urine a 0.417 ± 0.134
Uterus 0.591 ± 0.153 0.361 ± 0.145
Residual carcass 208.418 ± 11.160 0.200 ± 0.010
Results are expressed as percentage of injected radioactivity dose per gram of tissu
aOf blood, bone, bone marrow, brown adipose tissue, fat, plasma, skeletal muscle, s
organs were measured in their entiretythat is, to calculate AUC0–∞ and to estimate kel and t1/2.
Because plasma concentrations were given in SUV units,
the total clearance (CIT) is calculated as 1/AUC0–∞, and
the unit of CIT is then (g plasma/(g rat × min)).
Estimation of human radiation dose
Absorbed doses were calculated with the OLINDA/EXM
version 1.0 software (organ level internal dose assessment
and exponential modeling; Vanderbilt University, Nashville,
TN, USA), which applies the MIRD schema (developed by
the Medical Internal Radiation Dose committee of the Soci-
ety of Nuclear Medicine) for radiation dose calculations in
internal exposure. The software includes radionuclide infor-
mation and selection of human body phantoms. The resi-
dence times derived from the rat data were integrated as
the area under the time-activity curve. The residence times
were converted into corresponding human values byerator eluate in female rats
30 min 60 min 120 min 180 min
0.603 ± 0.271 0.705 ± 0.264 0.567 ± 0.226 0.497 ± 0.184
2.509 ± 1.359 2.563 ± 0.909 2.128 ± 0.953 1.668 ± 0.428
0.589 ± 0.132 0.820 ± 0.396 1.001 ± 0.363 0.963 ± 0.370
0.296 ± 0.051 0.705 ± 0.242 0.790 ± 0.366 0.710 ± 0.231
0.079 ± 0.040 0.084 ± 0.025 0.080 ± 0.041 0.052 ± 0.016
0.605 ± 0.229 0.471 ± 0.213 0.376 ± 0.201 0.316 ± 0.126
0.668 ± 0.283 0.615 ± 0.337 0.531 ± 0.302 0.431 ± 0.277
0.177 ± 0.093 0.145 ± 0.073 0.158 ± 0.151 0.099 ± 0.038
0.755 ± 0.462 0.617 ± 0.235 0.540 ± 0.204 0.439 ± 0.141
0.550 ± 0.191 0.465 ± 0.070 0.631 ± 0.426 0.520 ± 0.202
0.875 ± 0.328 0.823 ± 0.301 0.722 ± 0.324 0.679 ± 0.208
1.529 ± 0.450 1.490 ± 0.516 1.597 ± 0.627 1.178 ± 0.759
1.078 ± 0.520 1.136 ± 0.379 0.894 ± 0.450 0.754 ± 0.268
0.784 ± 0.429 1.343 ± 1.257 0.782 ± 0.286 0.750 ± 0.124
0.389 ± 0.211 0.364 ± 0.174 0.331 ± 0.164 0.346 ± 0.233
4.491 ± 2.419 4.451 ± 1.523 3.742 ± 1.602 2.865 ± 0.813
0.630 ± 0.230 0.506 ± 0.178 0.485 ± 0.229 0.382 ± 0.165
0.253 ± 0.080 0.214 ± 0.118 0.190 ± 0.078 0.143 ± 0.077
0.341 ± 0.142 0.312 ± 0.176 0.265 ± 0.089 0.263 ± 0.079
0.836 ± 0.204 0.785 ± 0.269 0.687 ± 0.201 0.661 ± 0.258
0.384 ± 0.117 0.471 ± 0.196 0.441 ± 0.255 0.369 ± 0.159
0.259 ± 0.143 0.225 ± 0.089 0.264 ± 0.193 0.181 ± 0.106
0.656 ± 0.327 0.607 ± 0.245 0.576 ± 0.347 0.473 ± 0.174
0.442 ± 0.172 0.636 ± 0.311 0.734 ± 0.187 0.469 ± 0.187
13.162 ± 3.607 3.526 ± 1.783 5.228 ± 2.368 2.314 ± 0.981
1.023 ± 0.482 1.149 ± 0.865 0.819 ± 0.553 0.941 ± 0.585
0.318 ± 0.036 0.266 ± 0.025 0.269 ± 0.023 0.262 ± 0.029
e (mean ± SD)
kin, and urine, only a small sample was taken and weighed. All other tissues/
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weights: (WTB,rat/WOrgan,rat) × (WOrgan,human/WTB,human),
where WTB,rat and WTB,human are the body weights of rat
and human (a 57-kg female or 70-kg male), respectively;
and WOrgan,rat and WOrgan,human are the organ weights of
rat and human (organ weights for a 57-kg female or 70-kg
male), respectively.
Statistical analysis
The mean values are calculated from the individual mea-
surements and expressed with an accuracy of one stand-
ard deviation (mean ± SD). Differences between genders
were assessed with Student’s t test.
Results
Animal and tissue/organ weights and ex vivo biodistribu-
tion data from the rats are summarized in Tables 1 and
2, and 180-min results visualized in Fig. 1. 68GaTable 2 Tissue/organ weights and ex vivo biodistribution of 68Ga/68
Tissue/organ Weight (g) 5 min
Adrenal glands 0.040 ± 0.012 0.635 ± 0.404
Blood a 1.556 ± 0.476
Bone (femur, both) a 0.285 ± 0.100
Bone marrow (femur, both) a 0.494 ± 0.061
Brain 1.633 ± 0.163 0.078 ± 0.020
Brown adipose tissue a 0.294 ± 0.099
Colon (without contents) 1.223 ± 0.424 0.230 ± 0.018
Fat (intraperitoneal) a 0.050 ± 0.019
Heart 1.086 ± 0.113 0.494 ± 0.075
Ileum (without contents) 3.923 ± 1.768 0.205 ± 0.088
Kidneys 2.113 ± 0.279 0.993 ± 0.730
Liver 12.497 ± 1.444 1.044 ± 0.516
Lungs 1.277 ± 0.133 0.608 ± 0.028
Pancreas 1.307 ± 0.301 0.246 ± 0.042
Plasma a 3.481 ± 0.980
Salivary glands 0.596 ± 0.060 0.351 ± 0.079
Skeletal muscle a 0.085 ± 0.069
Skin a 0.124 ± 0.074
Spleen 0.864 ± 0.135 0.520 ± 0.114
Stomach (without contents) 1.403 ± 0.241 0.222 ± 0.045
Testes 3.509 ± 0.214 0.076 ± 0.054
Thymus 0.497 ± 0.088 0.190 ± 0.033
Thyroids 0.020 ± 0.007 0.536 ± 0.040
Urinary bladder (without contents) 0.070 ± 0.015 0.267 ± 0.177
Urine a 0.758 ± 0.727
Residual carcass 289.423 ± 45.504 0.177 ± 0.082
Results are expressed as percentage of injected radioactivity dose per gram of tissu
aOf blood, bone, bone marrow, brown adipose tissue, fat, plasma, skeletal muscle, s
organs were measured in their entiretyradioactivity was slowly cleared from blood circulation
and excreted predominantly into the urine, with some
retention in the liver and kidneys. Interestingly, the 68Ga
radioactivity in female genital organs, i.e., the uterus and
ovaries, was considerable higher than in male genitals
(ovaries 0.750 %ID/g, uterus 0.941, testes 0.198 at
180 min). Plasma had also large difference 2.865 %ID/g
(female) vs. 1.544 (male) at 180 min. In vivo PET images
were in the line with ex vivo measurements (Fig. 2). Esti-
mated plasma pharmacokinetic parameters for 68Ga radio-
activity are given in Table 3. Plasma concentration was
relatively high at the final time point (180 min), which may
lead in uncertainty in the estimation of AUC0–∞.
The human residence times for the various source or-
gans and radiation dose estimates for 68Ga radioactivity,
extrapolated from rat biodistribution data, are listed in
Table 4. The estimations of the absorbed doses were cal-
culated for a 70-kg adult male and a 57-kg adult female.Ge generator eluate in male rats
30 min 60 min 120 min 180 min
0.303 ± 0.047 0.338 ± 0.040 0.355 ± 0.174 0.278 ± 0.011
1.119 ± 0.088 1.175 ± 0.128 0.970 ± 0.165 0.908 ± 0.157
0.387 ± 0.188 0.500 ± 0.176 0.657 ± 0.240 0.854 ± 0.256
0.354 ± 0.020 0.423 ± 0.066 0.394 ± 0.123 0.490 ± 0.064
0.041 ± 0.003 0.048 ± 0.006 0.034 ± 0.002 0.035 ± 0.007
0.279 ± 0.122 0.318 ± 0.075 0.255 ± 0.071 0.217 ± 0.070
0.260 ± 0.048 0.285 ± 0.038 0.227 ± 0.077 0.305 ± 0.066
0.069 ± 0.013 0.090 ± 0.031 0.069 ± 0.046 0.053 ± 0.009
0.338 ± 0.070 0.320 ± 0.032 0.270 ± 0.053 0.251 ± 0.042
0.186 ± 0.022 0.268 ± 0.074 0.222 ± 0.114 0.308 ± 0.081
0.359 ± 0.070 0.404 ± 0.026 0.343 ± 0.119 0.397 ± 0.025
0.514 ± 0.195 0.770 ± 0.336 0.746 ± 0.421 0.498 ± 0.209
0.479 ± 0.045 0.484 ± 0.196 0.455 ± 0.079 0.374 ± 0.037
0.207 ± 0.067 0.212 ± 0.031 0.181 ± 0.034 0.173 ± 0.016
2.078 ± 0.194 2.162 ± 0.251 1.639 ± 0.259 1.544 ± 0.203
0.304 ± 0.018 0.336 ± 0.058 0.331 ± 0.075 0.315 ± 0.034
0.125 ± 0.036 0.142 ± 0.019 0.151 ± 0.028 0.123 ± 0.023
0.157 ± 0.060 0.248 ± 0.038 0.204 ± 0.054 0.219 ± 0.037
0.383 ± 0.099 0.516 ± 0.193 0.582 ± 0.255 0.455 ± 0.129
0.227 ± 0.061 0.268 ± 0.036 0.250 ± 0.058 0.264 ± 0.048
0.075 ± 0.023 0.140 ± 0.020 0.175 ± 0.026 0.198 ± 0.018
0.137 ± 0.055 0.182 ± 0.050 0.141 ± 0.051 0.154 ± 0.064
0.355 ± 0.057 0.403 ± 0.131 0.415 ± 0.106 0.370 ± 0.105
0.553 ± 0.360 0.502 ± 0.191 0.478 ± 0.216 0.418 ± 0.259
1.342 ± 0.530 1.408 ± 0.736 3.111 ± 3.927 1.520 ± 0.894
0.218 ± 0.051 0.207 ± 0.039 0.215 ± 0.048 0.206 ± 0.038
e (mean ± SD)
kin, and urine, only a small sample was taken and weighed. All other tissues/
Fig. 1 Ex vivo biodistribution of 68Ga radioactivity in rats at 180 min post-injection. Statistically significant (P < 0.05) differences between female
and male are marked as asterisk
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for a 57-kg adult female was 0.0308 mSv/MBq, i.e.,
7.7 mSv from an intravenously injected radioactivity of
250 MBq. The corresponding estimates for 15-, 10-, 5-,
and 1-year-old and newborn females are presented in
Table 5. Estimated from female rat data, the absorbed
doses were the greatest in heart wall (0.501 mSv/MBq),
osteogenic cells (0.076 mSv/MBq), liver (0.072 mSv/MBq),
lungs (0.0502 mSv/MBq), and spleen (0.034 mSv/MBq). Ex-
trapolating from the male rat data, the effective dose for a
70-kg adult male was 0.0191 mSv/MBq, i.e., 4.8 mSv from
an intravenously injected radioactivity of 250 MBq. The
corresponding estimates for 15-, 10-, 5-, and 1-year-old
and newborn males are presented in Table 6. Estimated
from the male rat data, the absorbed doses were greatest
in heart wall (0.216 mSv/MBq), liver (0.0652 mSv/MBq),
osteogenic cells (0.0418 mSv/MBq), urinary bladder wall
(0.0382 mSv/MBq), and lungs (0.0245 mSv/MBq).
Discussion
The latest research has produced a series of new com-
pounds labeled with 68Ga, which is a positron-emitting
metal especially suitable for labeling of peptides and
PET. In this study, we investigated the absorption, distri-
bution, and excretion of 68Ga/68Ge radioactivity after a
single intravenous injection of 68Ge/68Ga generator elu-
ate in female and male rats over a period of 3 h.
The observed differences between the female and male
biodistribution data are probably, at least in part, due tothe small number of animals. However, higher concen-
trations of some elements, including iron, have been ob-
served in the organs of female rats than in male rats,
and since Ga3+ is transported into tissues in a similar
way as Fe3+, this may explain part of the gender differ-
ence observed in this study [5]. This, in addition to
higher injected radioactivity dose per gram, might in
part explain higher plasma values of female rats. Inter-
estingly, the estimated human radiation dose was higher
when using the female rat data than when using the
male rat data. Possible explanations for this include the
small sample size and/or actual gender dependent differ-
ences in handling certain elements [5]. The body weight
of female rats was approximately 100 g lower than that
of male rats. However, both genders received an identi-
cal 50-MBq dose of 68Ga eluate. This may also be one
source of difference.
When the studies started, the 68Ge/68Ga generator
was already used for 7 month; the studies lasted up to
5 month. According to manufacturer’s metals screen
by inductively coupled plasma mass spectrometry
(ICP-MS), the 68Ge/68Ga generator (no. 1484-7, with
1850-MBq nominal radioactivity) had antimony
0.004 ppm, boron 0.17 ppm, sodium 0.56 ppm, titan-
ium 0.069 ppm, and zinc 0.006 ppm, which reflects the
typical metal impurities in the eluate. In the respective
Ph. Eur. monograph, only zinc and iron are mentioned
as metal impurities, because they might interfere as 3+
metals with the Ga-68 during the labeling. The limit of
Fig. 2 PET images and time-activity curves. Left panels: Healthy Sprague-Dawley rats were intravenously injected with 68Ge/68Ga generator eluate.
Images are summations from 0–180 min after injection and displayed in the same color scale as percentage of injected dose per gram of tissue
(%ID/g). Male rat: 350 g, 50 MBq (0.007 MBq/kg); female rat 259 g, 48 MBq (0.005 MBq/kg). Right panels: Mean time-activity curves of 68Ga radio-
activity in selected organs/tissues of male (upper) and female (lower) rats. Error bars denote standard deviation. According to Student’s t test, the
differences in blood (P = 0.00026) and testes vs. uterus (P < 0.0001) were statistically significant at 180-min post-injection. The “blood” values were
obtained from heart left ventricle
Table 3 Plasma pharmacokinetic parameters for 68Ga
radioactivity after an intravenous bolus injection of 68Ga/68Ge
generator eluate in rats
Parameter Males (n = 21) Females (n = 21)
kel (1/h) 0.175349 0.201682
t1/2 (h) 3.952956 3.436839
AUC0–∞ (h × g/g) 48.66309 65.64807
ClT (g plasma/(g rat × h)) 0.020549 0.015233
AUC area under the curve, kel elimination rate constant, ClT total clearance, C0
initial concentration, t1/2 plasma half-life
Autio et al. EJNMMI Research  (2015) 5:40 Page 6 of 11zinc and iron is 10 μg/GBq. The generator has a zinc
level of 0.02 μg/GBq, which is well below the limit, and
iron was not detected by ICP-MS by a detection limit
of 0.006 ppm, which also correlates to a value way
below the limit. The 68Ge breakthrough was
0.000017 % correlated to the 68Ga radioactivity of the
eluate at the reference date. This value is well below
the limit of 68Ge-breakthrough mentioned in the re-
spective Ph. Eur. monograph. Thus, it was estimated
that these levels of metal impurities and 68Ge break-
through had no effect on the results. However, the
chemical form of 68Ga used in this study (68Ga eluate
was mixed with a phosphate-buffered saline) might be
Table 4 Human residence times and radiation dose estimates for 68Ga radioactivity extrapolated from the rat biodistribution data
Organ Residence time (h) Dose (mSv/MBq)




Bone marrow 0.0688 0.0425
Brain 0.0064 0.0043 0.00591 0.00372
Breasts 0.01790 0.01260
Gallbladder wall 0.01950 0.01680
Lower large intestine wall 0.01520 0.01260
Small intestine 0.01480 0.01350
Stomach wall 0.01870 0.01400
Upper large intestine wall 0.01580 0.01360
Heart wall 0.0117 0.0072 0.50100 0.21600
Kidneys 0.0149 0.0118 0.03360 0.02430
Liver 0.1716 0.2226 0.07220 0.06520
Lungs 0.0591 0.0352 0.05020 0.02450
Muscle 0.4238 0.2484 0.01900 0.00928
Ovaries 0.0006 0.03080 0.01290
Pancreas 0.0027 0.0013 0.02860 0.01530
Red marrow 0.0688 0.0425 0.02530 0.01850
Osteogenic cells 0.07580 0.04180
Skin 0.01170 0.0097300
Spleen 0.0081 0.0069 0.03370 0.02280
Thymus 0.03050 0.01860
Thyroid 0.0008 0.0005 0.02640 0.02100
Testes 0.0005 0.00934
Urinary bladder wall 0.01350 0.03820
Uterus 0.0006 0.01140 0.01320
Whole body 0.02560 0.01730
Effective dose 0.0308 0.0191
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68Ga-labeled radiopharmaceuticals. In radiolabeling
peptides, 68Ga is reacted with chelate-conjugated pep-
tides at elevated temperature, which should accelerate
the hydrolysis reaction of Ga that does not form com-
plex with peptide-chelate conjugate.
The whole-body distribution of 68Ga radioactivity re-
ported here is in line with previous publications. Velik-
yan and co-workers studied biodistribution of 68GaCl3 in
healthy Sprague-Dawley rats in order to control the or-
gans where the accumulation would occur in case of im-
pure tracer or in vivo release of 68Ga from the tracer
(68Ga-DOTATOC and 68Ga-DOTATATE). The 68GaCl3
was acetate buffered to pH of 4.6 and formulated with
phosphate-buffered saline (pH 7.4) for i.v. injection. The
68Ga radioactivity concentration at 75-min post-injectionwas the highest in the blood, and the accumulation in
the heart, lung, liver, and spleen was considerably higher
as compared to that of peptide tracers [6]. Previously, we
i.v. injected NaOH neutralized 68Ga-chloride (12 MBq from
Cyclotron Co. 68Ge/68Ga generator, Obninsk, Russia) in
anesthetized, athymic, male Hsd/RH-rnu/rnu rats having
subcutaneous tumor xenografts and reported the following
SUVs at 90 min after injection (the values at 120 min of the
present report are given in the parentheses): blood 2.7 ± 0.3
(3.074 ± 0.337), liver 5.9 ± 3.3 (2.280 ± 0.918), lung 1.9 ± 0.8
(1.445 ± 0.195), muscle 0.2 ± 0.03 (0.478 ± 0.067), and skin
0.5 ± 0.1 (0.662 ± 0.233) [7]. Subsequently, we also studied
distribution of 68GaCl3 (Cyclotron Co., Obninsk, Russia) in
healthy C57BL/6 N mice. The 68GaCl3 was neutralized with
1 mol/l sodium hydroxide to pH of 7, and the final product
contained 13 % of colloidal forms of 68Ga as determined by
Table 5 Additional dosimetry estimates based on a female rat distribution data
Absorbed dose per unit radioactivity administered (mSv/MBq)
Organ 15-year-olds 10-year-olds 5-year-olds 1-year-olds Newborn
(50 kg) (30 kg) (17 kg) (10 kg) (5 kg)
Adrenals 0.0220 0.0337 0.0521 0.0922 0.212
Brain 0.00526 0.00685 0.00531 0.0148 0.0333
Breasts 0.0178 0.0304 0.0483 0.0885 0.211
Gallbladder wall 0.0194 0.0307 0.0466 0.0875 0.217
Lower large intestine wall 0.0144 0.0236 0.0374 0.0696 0.176
Small intestine 0.0157 0.0251 0.0400 0.0762 0.182
Stomach wall 0.0187 0.0285 0.0451 0.0849 0.202
Upper large intestine wall 0.0153 0.0247 0.0400 0.0754 0.185
Heart wall 0.576 0.893 1.44 2.61 5.11
Kidneys 0.0363 0.0521 0.0777 0.139 0.351
Liver 0.0722 0.109 0.164 0.315 0.721
Lungs 0.0575 0.0823 0.125 0.239 0.611
Muscle 0.0201 0.0382 0.109 0.215 0.305
Ovaries 0.0349 0.0893 0.1550 0.349 0.710
Pancreas 0.0335 0.0608 0.0823 0.166 0.496
Red marrow 0.0262 0.0455 0.0828 0.201 0.737
Osteogenic cells 0.0745 0.117 0.194 0.452 1.39
Skin 0.0116 0.0187 0.0306 0.0595 0.151
Spleen 0.0391 0.0602 0.0955 0.174 0.449
Testes 0.0126 0.0203 0.0327 0.0637 0.156
Thymus 0.0311 0.0413 0.0622 0.107 0.237
Thyroid 0.0342 0.0537 0.113 0.213 0.314
Urinary bladder wall 0.0733 0.113 0.180 0.345 0.895
Uterus 0.0118 0.0721 0.110 0.198 0.136
Total body 0.0258 0.0420 0.0678 0.133 0.338
Effective dose (mSv/MBq) 0.03110 0.0582 0.096800 0.20100 0.48500
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was quite similar to the present study. The highest level of
68Ga radioactivity at 3-h post-injection was found in the
blood and liver followed by spleen, kidneys, bone with bone
marrow, and lung, respectively [8]. Nanni and co-workers
have studied 68Ga-citrate in patients with infectious dis-
eases [9]. Since citrate is only a weak chelator of 68Ga, the
radionuclide is rapidly released in vivo and subsequently
binds to transferrin and some other plasma proteins. The
biodistribution of 68Ga-citrate may actually resemble that
of free 68Ga or the eluate of the 68Ge/68Ga generator. In
clinical whole-body PET scanning, 68Ga-citrate showed
relatively high vascular radioactivity, moderate hepatic up-
take, mild bone marrow radioactivity, and no bowel radio-
activity. The relatively high vascular radioactivity, which is
not seen in 67Ga-citrate scintigraphy, was a particularly in-
teresting finding. In the current rat study, the elimination
of radioactivity in urine and feces at each time point andthe overall mass balance as a percentage of administered ra-
dioactivities could not be determined since urine or feces
were sampled, not collected in their entirety. The observed
high plasma values in rats supports that the 68Ga radio-
activity is bound to transferrin.
68Ga has been used extensively for the labeling of syn-
thetic peptides. However, there are only few human dos-
imetry reports available, including, for example, those on
peptide analogues that bind to somatostatin receptors
(Table 7) [10–15]. The effective dose of the 68Ge/68Ga
generator eluate reported here is somewhat higher than
that of 68Ga-DOTANOC and 68Ga-DOTATOC [10, 11].
The higher dose of the 68Ge/68Ga generator eluate can be
explained by the slow clearance from the blood and the re-
tention in the liver. The biodistribution of 68Ga-labeled
complexes is determined by the pharmacokinetics of the
complexing molecules, such as peptides, and not by the in-
corporated Ga3+.
Table 6 Additional dosimetry estimates based on a male rat distribution data
Absorbed dose per unit radioactivity administered (mSv/MBq)
Organ 15-year-olds 10-year-olds 5-year-olds 1-year-olds Newborn
(50 kg) (30 kg) (17 kg) (10 kg) (5 kg)
Adrenals 0.0201 0.0313 0.0491 0.0897 0.231
Brain 0.0039 0.00523 0.00723 0.0115 0.0259
Breasts 0.01580 0.0258 0.0416 0.0790 0.195
Gallbladder wall 0.0203 0.0312 0.0483 0.0921 0.228
Lower large intestine wall 0.00149 0.0248 0.0396 0.0746 0.191
Small intestine 0.0167 0.0267 0.0427 0.0818 0.199
Stomach wall 0.0175 0.0275 0.0440 0.0843 0.206
Upper large intestine wall 0.0165 0.0266 0.0428 0.0814 0.202
Heart wall 0.280 0.435 0.700 1.27 2.49
Kidneys 0.0295 0.0421 0.0633 0.113 0.282
Liver 0.0876 0.133 0.199 0.384 0.888
Lungs 0.0352 0.0504 0.0765 0.147 0.374
Muscle 0.0137 0.0253 0.0665 0.134 0.199
Ovaries 0.0175 0.0258 0.0461 0.0799 0.194
Pancreas 0.02060 0.0361 0.0501 0.098 0.275
Red marrow 0.02190 0.0355 0.0643 0.1620 0.630
Osteogenic cells 0.05470 0.0850 0.1390 0.3220 0.974
Skin 0.0121 0.0198 0.0326 0.0639 0.164
Spleen 0.0327 0.0503 0.0801 0.1460 0.378
Testes 0.0185 0.1120 0.1320 0.1810 0.269
Thymus 0.02270 0.0324 0.0501 0.0911 0.214
Thyroid 0.0330 0.0514 0.11 0.206 0.298
Urinary bladder wall 0.0488 0.0760 0.122 0.232 0.6040
Uterus 0.0165 0.0262 0.0424 0.0810 0.197
Total body 0.0220 0.0360 0.0584 0.1150 0.292
Effective dose (mSv/MBq) 0.02530 0.05580 0.081000 0.14600 0.34300





68Ga-DOTANOC 0.025 Pettinato 2008 [10]
68Ga-DOTATOC 0.023 Hartmann 2009 [11]
68Ga-DOTATATE 0.021 Sandström 2013 [12]
68Ga-NOTA-2Rs15d 0.0218a Xavier 2013 [13]
BAY86-7548 0.051 Roivainen 2013 [14]
18F-FDG 0.0190 ICRP Publication 1998 [15]
68Ga-eluate 0.0308b, 0.0191c Present study
aExtrapolated from tumor xenograft mice
bObtained by using female rat data
cObtained by using male rat data
Autio et al. EJNMMI Research  (2015) 5:40 Page 9 of 11The radiation dose resulting from the i.v. injection of
68Ga-citrate has been estimated from 67Ga-citrate data
[16]. The estimated absorbed dose for total body, calcu-
lated assuming a uniform distribution of radioactivity,
was 0.052 rads/mCi. For 68Ge/68Ga generator eluate, the
total-body radiation dose estimates for female and male
rats were 0.02560 and 0.01730 mSv/MBq, respectively.
However, the 68Ga-citrate and 68Ga-eluate values are not
directly comparable because they are expressed with dif-
ferent units (rads/mCi vs. mSv/MBq), but assuming that
only gamma radiation is taken into account for the en-
ergy dose, the rad value can be converted into the
equivalent dose value rem, thus giving an absorbed dose
of 0.052 rem/mCi = 0.014 mSv/MBq. There are limited
number of studies comparing the PET tracer dosimetry
in animals and humans. Table 8 contains a list of refer-
ence studies in which human effective doses derived
from preclinical studies are reported and compared to
Table 8 Comparison of preclinical studies with the human








11C-6-OH-BTA-1 0.0065a 0.0045 Parsey 2005;
Scheinin 2007 [17, 18]
11C-MPGA 0.0048 0.0053 Santens 1998 [19]
6-18 F-Fluoro-L-Dopa 0.0539b 0.0199 Harvey 1985;
Brown 1998 [20, 21]
18 F-FET 0.0186 0.0165 Tang 2003; Pauleit
2003 [22, 23]
11C-Choline 0.0028 0.0044 Tolvanen 2010 [24]
aMales only
bED value calculated with the biological risk weight factors in accordance with
ICRP 30 publication
Autio et al. EJNMMI Research  (2015) 5:40 Page 10 of 11effective doses from human measurements [17–24]. The
absorbed doses and effective doses from the in vivo stud-
ies in rats may be different from those obtained in hu-
man studies because of the dissimilar physiology of
rodents and humans. For example, the blood flow rate
has a remarkable influence on the time-activity curve
shape, the area under the curve, and the measured num-
ber of disintegrations.
In this study, scaling between rat and human data was
performed using the overall non-organ-specific weight.
In general, interspecies extrapolation of biokinetic data
is based on the fact that the cellular structures and bio-
chemistry are remarkably alike across the entire animal
kingdom. Despite these similarities, however, the ex-
trapolation of biokinetic data from laboratory animals to
humans entails uncertainty, particularly for the liver, due
to the qualitative differences among various species in
the handling of many elements by this organ. Allometric
scaling from laboratory animals to humans on the basis
of body weight or surface area is the most commonly
used method. It is based on the assumption that the bio-
kinetics of compounds primarily depends on the meta-
bolic rate of the animal and that the metabolic rate is a
function of the body weight or body surface area of the
animal. Yet, several other scaling methods have been
proposed [25], based on, for example, the modeling of
pharmacokinetic parameters where the variation of
serum protein binding between species is taken into
account.Conclusions
The estimated human radiation burden of the 68Ge/68Ga
generator eluate was slightly higher for females and similar
for males as compared with somatostatin ligands
68Ga-DOTANOC,68Ga-DOTATOC, and 68Ga-DOTA-
TATE, which is probably due to the retention in the
liver and spleen. Our results revealed some differencesbetween female and male rat data, which, at least in part,
may be explained by the small sample size.
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